eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

ELIQUIS (apixaban) dosing for patients with DVT / PE

ELIQUIS for the treatment of DVT / PE and prevention of recurrent DVT / PE

The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding.1

Duration of overall treatment should be individualised after careful assessment of the treatment benefit against the risk for bleeding.1

* As per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation)

large x icon

No dose adjustment for DVT / PE patients, based on age, weight or those with mild-to-moderate renal impairment.1 ELIQUIS should be used with caution in patients with severe renal impairment (CrCl 15–29 ml/min) for the treatment of DVT / PE and prevention of recurrent DVT / PE. ELIQUIS is not recommended in patients with CrCl <15 ml/min, or in patients undergoing dialysis.1

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

BD = Twice Daily   CrCl = Creatine Clearance   DVT = Deep Vein Thrombosis   LMWH = Low Molecular Weight Heparin   PE = Pulmonary Embolism

Reference

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.